All Substitutes
Loading...
Disclaimer
Did you find this information helpful?


Pegadria 50mg Injection
Prescription Required
Salt Composition : Pegylated Liposomal Doxorubicin
Manufacturer : INTAS PHARMACEUTICALS LTD
Origin of Medicine : India
1 Vial(s) Of 25ml
PAP Information : Buy 2, Get 1 Free. Contact us for more updates.
Program Overview: INTAS PHARMACEUTICALS LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of Pegardria 50mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 2 vials of Pegardria 50mg injection, and you will receive 1 free additional vial. Therefore, if eligible, you will have to pay only Rs.13,898 for three vials, which is Rs.4,633 per vial.
With MrMed's MRP discount of Rs.1651 per vial and Intas’s PAP program, the overall savings is over 12 thousand rupees.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Pegadria Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for pegylated liposomal doxorubicin 50mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Intas can avail of it without having to purchase the medication from MrMed.
Patient Assistance Programs
Program Overview: INTAS PHARMACEUTICALS LTD, Patient Assistance Program (PAP) is dedicated to helping patients in need of Pegardria 50mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 2 vials of Pegardria 50mg injection, and you will receive 1 free additional vial. Therefore, if eligible, you will have to pay only Rs.13,898 for three vials, which is Rs.4,633 per vial.
With MrMed's MRP discount of Rs.1651 per vial and Intas’s PAP program, the overall savings is over 12 thousand rupees.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Pegadria Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for pegylated liposomal doxorubicin 50mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Intas can avail of it without having to purchase the medication from MrMed.
Introduction to Pegadria 50mg Injection
Pegadria 50mg Injection is an anticancer medication that contains the active constituent doxorubicin encapsulated in a closed lipid sphere (liposome). Cancer is a disease in which cells multiply in an uncontrolled and abnormal manner. This medication treats breast cancer, ovarian cancer, multiple myeloma (cancer of white blood cells called plasma cells), and AIDS-related Kaposi’s sarcoma.
People with HIV infection have the highest risk of Kaposi’s sarcoma (cancer that forms in the lining of the lymph and blood vessels). Pegadria 50mg Injection may be given alone or in combination with other anticancer medicines. This medication is not recommended for adolescents and children.
Use effective birth control during the treatment and at least six months after the last dose. It is important to tell your doctor if you are allergic to peanuts or soya if you are receiving medicines for heart or liver disorders, has diabetes, Kaposi’s sarcoma, or have oral problems before taking Pegadria 50mg Injection.
Uses of Pegadria 50mg Injection
- Breast cancer
- Ovarian cancer
- Multiple myeloma
- AIDS-related Kaposi’s sarcoma
Therapeutic Effects of Pegadria 50mg Injection
Pegadria 50mg Injection is a new class of drug formulations delivered in vesicles called liposomes. The mechanism of action of doxorubicin HCl is related to its ability to bind DNA and inhibit nucleic acid synthesis. Studies have demonstrated that the drug penetrates rapidly into the cell, binds to certain proteins in DNA, and thereby inhibits cell division and nucleic acid synthesis.
Interaction of Pegadria 50mg Injection with other drugs
Inform your doctor about any prescribed medications, over-the-counter medicines, nutrition or vitamin supplements, and herbal products that you are taking or have taken before the treatment. Certain medications may interact with Pegadria 50mg Injection and can cause undesirable side effects.
More Information about Pegadria 50mg Injection
- Keep Pegadria 50mg Injection out of sight and reach of children.
- Store refrigerated at 2°C - 8°C. Do not freeze.
How to consume Pegadria 50mg Injection
The drug should be administered only by physicians experienced with cancer chemotherapy. Your physician will determine the dose and frequency of administration based on the type of cancer and severity of the disease. Generally, for breast and ovarian cancer, the medicine is administered intravenously at a dose of 50 mg/m2 body surface once every 4 weeks for at least 4 courses. For treating AIDS-Kaposi Sarcoma, the drug is administered intravenously at a dose of 20 mg/m2 body surface once every two- to- three weeks only after the failure of prior systemic chemotherapy or intolerance to such therapy. For treating multiple myeloma, first bortezomib is administered at a dose of 1.3 mg/m2 as intravenous bolus on days 1, 4 , 8 and 11, every three weeks, then pegylated liposomal doxorubicin 30 mg/m2 should be administered as a 1-hr intravenous infusion on day 4 following bortezomib.
Safety Advices for Pegadria 50mg Injection
Pregnancy
Pegadria 50mg Injection may harm the unborn baby. You need to tell your physician if you are pregnant or planning to get pregnant before taking this medicine.
Breast Feeding
Stop breastfeeding before starting treatment with Pegadria 50mg Injection. You need to tell your physician if you are breastfeeding before taking this medicine.
Lungs
It is unknown whether Pegadria 50mg Injection can be given to patients with lung diseases. Please consult your physician if you have any lung problems.
Liver
You need to tell your physician if you have any liver disorders before taking Pegadria 50mg Injection.
Alcohol
It is not known whether it is safe to consume alcohol with Pegadria 50mg Injection. Please consult your doctor.
Driving
Pegadria 50mg Injection may cause tiredness or sleepiness. Avoid driving if you are unwell. Please consult your doctor for more advice.
Side Effects of Pegadria 50mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
Serious
- Fever, tiredness, bruising or bleeding
- Severe diarrhea, sores in mouth, nausea, vomiting
- Lung infections, shortness of breath
- Severe stomach pain
- Severe weakness
Common
- Low blood cell counts
- Hair loss
- Decreased appetite
- Skin rashes
- Pain in the muscles and joints
- Constipation
- Feeling confused, difficulty sleeping
- Headache, dizziness, sleepiness
- Change in taste
- High or low blood pressure
- Excessive sweating
- Pain when passing urine
- Weight loss
- Muscle spasms
- Fast heartbeat
Word of Advice
Avoid prolonged sun exposure and unnecessary heat exposure (such as hot dishwater and long hot baths). Avoid pressure on elbows, knees, and soles of feet (such as leaning on elbows, kneeling, and long walks). Wear loose clothing. Keep this medicine out of sight and reach of children. Store the tablets at room temperature. Avoid keeping the tablet in direct sunlight or excessive moisture. This drug may cause dizziness. If you are affected by this side effect, do not drive, use machinery, or do anything that needs alert until you can do it safely.
FAQs
Q 1. What is the use of Pegadria 50mg Injection?
This medication is used to treat breast cancer, ovarian cancer, multiple myeloma (cancer of white blood cells called plasma cells) and AIDS-related Kaposi’s sarcoma.
Q 2. Is it safe to use Pegadria 50mg Injection while driving?
No, it is unsafe to use this medication while driving and handling heavy machinery as it causes lack of concentration and alertness.
Q 3. How does Pegadria 50mg Injection work?
It damages the genetic material (DNA) of the cancer cells and stops their growth and multiplication
Q 4. What are the side effects of Pegadria 50mg Injection?
The common side effects of these medications are nausea, vomiting, rash, weakness, low blood platelets, Fatigue, Fever, Loss of appetite, Anemia, and Constipation.
Q 5. Is it safe to use Pegadria 50mg Injection during pregnancy?
It is unsafe to use this medication in patients planning for pregnancy or during pregnancy and breastfeeding mothers as it causes harmful effects for the baby.
Fact Box of Pegadria 50mg Injection
Molecule Name: Pegylated Liposomal Doxorubicin | Therapeutic effects: Antineoplastics |
Pharmacological class: Anthracyclines | Indications: 1. Breast cancer 2. Ovarian cancer 3. Multiple myeloma 4. AIDS-related Kaposi’s sarcoma |
References
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Cytotoxic agents, 12th edition, 2011, 1714.
- KD Tripathi, Essentials of Medical Pharmacology, Anticancer drugs, 7th edition, 2013, 867.
- Baxter Holding BV, European medicines agency (ema), [Revised on May 2006] [ Accessed on 4th Dec 2021], https://www.ema.europa.eu/en/documents/product-information/caelyx-pegylated-liposomal-epar-product-information_en.pdf
- Ben Venue Laboratories, Inc, US Food and Drug Administration, [Revised on May 2007] [ Accessed on 4th Dec 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.